MedTrace Logo

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

NCT07602855 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2026-05-22

No results posted yet for this study

Summary

This is an early-phase clinical study investigating a new combination treatment, Ris-Rez given with ivonescimab for adults with advanced solid cancers. The study aims to determine:

* What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects?
* How does the body handle the drug(s)?
* What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?

Conditions

Interventions

BIOLOGICAL

Ris-Rez

Ris-Rez will be administered

BIOLOGICAL

Ivonescimab

Ivonescimab will be administered

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-08
Primary Completion
2029-07-05
Completion
2030-01-04
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07602855 on ClinicalTrials.gov